Video

Frontline Treatment Options for Lower-Risk MDS

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

Related Videos
2 KOLs are featured in this series
2 KOLs are featured in this series
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Video 6 - 2 KOLs are featured in, "Other trials of note investigating targeted therapies in later line HR+/HER2- mBC"
Video 5 - 2 KOLs are featured in, "Targeted Therapies in HR+/HER2- mBC: CAPItello-291"
A panel of 3 experts on CLL
A panel of 3 experts on CLL
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)